TaiMed Biologics Inc. (TPEX:4147)
Taiwan
· Delayed Price · Currency is TWD 79.70
+0.70 (0.89%)
Aug 15, 2025, 1:30 PM CST
TaiMed Biologics Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Net Income | -243.51 | -201.83 | -194.81 | -269.29 | -470.93 | -183.3 | Upgrade
|
| Depreciation & Amortization | 149.41 | 150.1 | 150.67 | 151.73 | 152.13 | 137.12 | Upgrade
|
| Other Amortization | 4.18 | 4.18 | 4.72 | 4.72 | 4.53 | 2.66 | Upgrade
|
| Loss (Gain) From Sale of Assets | -0.06 | 2.32 | - | - | 24.18 | 7.84 | Upgrade
|
| Loss (Gain) From Sale of Investments | 1.75 | - | 29.05 | 122.81 | -26.76 | 63.13 | Upgrade
|
| Stock-Based Compensation | 7.65 | 25.36 | 10.51 | 12.27 | 10.22 | 16.68 | Upgrade
|
| Other Operating Activities | 96.53 | 80.78 | 5.82 | 168.85 | 101.38 | -15.5 | Upgrade
|
| Change in Accounts Receivable | 72.45 | 57.47 | -62.24 | 59.54 | 97.94 | -53.59 | Upgrade
|
| Change in Inventory | 182.19 | 185.47 | 110.85 | -382.84 | 14.84 | -384.99 | Upgrade
|
| Change in Accounts Payable | 1.86 | -12.74 | 13.41 | -122.49 | 116.79 | -130.24 | Upgrade
|
| Change in Unearned Revenue | -144.4 | -113.31 | -27.93 | -339.16 | 113.91 | 83.16 | Upgrade
|
| Change in Other Net Operating Assets | -534.44 | -557.36 | -65.64 | -11.33 | -349.5 | 255.09 | Upgrade
|
| Operating Cash Flow | -406.39 | -379.55 | -25.6 | -605.21 | -211.28 | -201.94 | Upgrade
|
| Capital Expenditures | -12.58 | -8.06 | -6.15 | -3.56 | -9.69 | -53.61 | Upgrade
|
| Sale of Property, Plant & Equipment | - | - | - | - | 0.41 | 2 | Upgrade
|
| Sale (Purchase) of Intangibles | -3.2 | -11.3 | - | -1.21 | -3.87 | -332.16 | Upgrade
|
| Investment in Securities | 544.98 | -695.39 | -12.88 | 110.88 | 204.07 | 273.36 | Upgrade
|
| Other Investing Activities | 0.12 | -0.1 | 2.58 | - | - | 1.25 | Upgrade
|
| Investing Cash Flow | 529.31 | -714.84 | -16.46 | 106.12 | 190.92 | -109.16 | Upgrade
|
| Short-Term Debt Issued | - | - | - | 200 | - | - | Upgrade
|
| Long-Term Debt Issued | - | - | - | - | - | 536 | Upgrade
|
| Total Debt Issued | - | - | - | 200 | - | 536 | Upgrade
|
| Short-Term Debt Repaid | - | -200 | - | - | - | - | Upgrade
|
| Long-Term Debt Repaid | - | -28.98 | -16.05 | -1.98 | -1.93 | -1.91 | Upgrade
|
| Total Debt Repaid | -29.2 | -228.98 | -16.05 | -1.98 | -1.93 | -1.91 | Upgrade
|
| Net Debt Issued (Repaid) | -29.2 | -228.98 | -16.05 | 198.02 | -1.93 | 534.09 | Upgrade
|
| Issuance of Common Stock | 8.73 | 1,645 | 35.28 | 10.31 | 4.71 | 1.95 | Upgrade
|
| Other Financing Activities | - | -4.27 | - | 0.05 | 0.01 | - | Upgrade
|
| Financing Cash Flow | -20.47 | 1,412 | 19.23 | 208.38 | 2.79 | 536.04 | Upgrade
|
| Foreign Exchange Rate Adjustments | -15.09 | 11.54 | -0.28 | 13.21 | -2.9 | -5.78 | Upgrade
|
| Net Cash Flow | 87.36 | 329.22 | -23.1 | -277.51 | -20.47 | 219.16 | Upgrade
|
| Free Cash Flow | -418.97 | -387.61 | -31.75 | -608.77 | -220.96 | -255.55 | Upgrade
|
| Free Cash Flow Margin | -70.06% | -63.52% | -6.46% | -108.13% | -53.44% | -35.37% | Upgrade
|
| Free Cash Flow Per Share | -1.51 | -1.45 | -0.13 | -2.41 | -0.88 | -1.01 | Upgrade
|
| Cash Interest Paid | 12.71 | 12.71 | 14.76 | 9.88 | 7.44 | 3.84 | Upgrade
|
| Levered Free Cash Flow | -190.21 | -268.47 | 82.39 | -217.42 | -191.55 | -673.15 | Upgrade
|
| Unlevered Free Cash Flow | -183.07 | -260.59 | 91.65 | -211.11 | -186.9 | -670.59 | Upgrade
|
| Change in Working Capital | -422.34 | -440.47 | -31.56 | -796.29 | -6.02 | -230.56 | Upgrade
|
Updated Mar 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.